Drug Profile

Exosome intravenous therapeutic - EVerZom

Alternative Names: EViv; Naïve exosome intravenous - EVerZom

Latest Information Update: 18 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EVerZom
Class Exosome therapies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Liver failure
Research Acute kidney injury

Most Recent Events

10 Nov 2025 Genfit enters research collaboration with EVerZom to advance Exosome intravenous therapeutic for Acute-on-chronic liver failure
20 Dec 2023 Early research in Acute kidney injury in France (IV) (EVerZom pipeline, December 2023)
20 Dec 2023 Preclinical trials in Liver failure in France (IV) (EVerZom pipeline, December 2023)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com